HYDERABAD, India – India may have a proven track record developing generics, but it is limping far behind other countries in the discovery and development of new drugs, areas which call for entirely new skill sets and investments.
NEW DELHI, India – The EMA has recommended suspending the Hyderbad-based contract research organisation (CRO) GVK Biosciences on charges of data manipulation, a decision that once again shines a spotlight on the issue of Western drug firms outsourcing clinical trials to CROs to cut costs.
NEW DELHI, India – The EMA has recommended suspending the Hyderbad-based contract research organisation (CRO) GVK Biosciences on charges of data manipulation, a decision that once again shines a spotlight on the issue of Western drug firms outsourcing clinical trials to CROs to cut costs.
NEW DELHI – In twin developments, an Indian patent office rejected U.S.-based Gilead Sciences Inc.'s patent application for its blockbuster hepatitis C virus (HCV) drug Sovaldi (sofosbuvir), leaving the door open for low-cost generic versions of a drug that is currently out of reach of most Indian patients. However, the court also granted regulatory approval for the drug, making India the first Asian country to do so.
NEW DELHI – In twin developments, an Indian patent office rejected U.S.-based Gilead Sciences Inc.'s patent application for its blockbuster hepatitis C virus (HCV) drug Sovaldi (sofosbuvir), leaving the door open for low-cost generic versions of a drug that is currently out of reach of most Indian patients.
NEW DELHI – India's attempts to enter into a Regional Comprehensive Economic Partnership (RCEP) deal among 16 countries in Asia are likely to have a significant impact on the biopharma industry, but analysts are divided as to what that will be.
NEW DELHI – India’s attempts to enter a Regional Comprehensive Economic Partnership (RCEP) deal among 16 countries in Asia are likely to have a significant impact on the biopharma industry, but analysts are divided as to what that will be.
NEW DELHI – India's Supreme Court has dismissed German multinational Bayer AG's appeal against attempts to make and sell cheaper generic versions of its cancer drug, Nexavar (sorafenib tosylate), used to treat liver and rectal cancers.
NEW DELHI – India's Supreme Court has dismissed German multinational Bayer AG's appeal against attempts to make and sell cheaper generic versions of its cancer drug, Nexavar (sorafenib tosylate), used to treat liver and rectal cancers.
